Gastrointestinal Drugs Market Research Report- Forecast till 2030

Gastrointestinal Drugs Market Research Report: Information by Drug Class (Acid Neutralizers, Anti-Inflammatory Drugs, Antidiarrheal and Laxatives, Antiemetic and Antinauseants, Biologics and others), Route of Administration (Oral, Parenteral and Rectal), Application (Inflammatory Ulcerative Colitis, Irritable Bowel Syndrome, Crohn's Disease, Celiac Disease, Gastroenteritis and others), Distribution Channel (Retail Pharmacies, Online Pharmacies and Hospital Pharmacies) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa)

ID: MRFR/Pharma/0115-HCR | November 2022 | Region: Global | 90 Pages         

Gastrointestinal Drugs Market Speak to Analyst Request a Free Sample

Gastrointestinal Drugs Market Overview


The gastrointestinal drugs market is expected to grow at a higher CAGR of 5.03% in the global market to account for a higher market value of approximately USD 75.56 billion by the end of the forecasted period from 2020-2030. Gastrointestinal drug as the name suggests is used to treat gastrointestinal problems prevailing almost all across the globe. An increasing geriatric population leads to more gastrointestinal problems. Also, the changing lifestyle is the main reason that drives the gastrointestinal problem in many regions. The increasing investment done by governments of various nations in the field of life science and the health care sector increases the market size of the gastrointestinal drugs market. Additionally, the increasing number of patients suffering from gastrointestinal problems is another major growth driving factor.


COVID 19 Analysis


The global pandemic of COVID 19 has affected a large section of society. Most of the people who had got Corona Virus is struggling with gastric issues. Owing to the increasing cases of gastric diseases, huge investments have been made by manufacturers for the development of gastrointestinal treatment. This investment gives rise to increasing medication demand and hence increase the gastrointestinal drugs market size in the global market.


The global pandemic of COVID 19 has a positive effect on the global gastrointestinal drugs market share of this drug. The market share for this drug is also expected to grow furthermore in the coming years.


Market Dynamics


Drivers


The increasing number of gastrointestinal diseases among old age people is one of the major driving factors. Increasing investment by governments of various countries in the field of life science and the healthcare sector accelerates the growth rate. Various trials conducted by various pharmaceutical companies drive the market in the global gastrointestinal drugs market. Increasing the introduction of products recently also drives the market.


Opportunities


The gastrointestinal drugs market is growing tremendously in the global market. High investment done by the various practitioners and pharmaceutical companies provides growth opportunities during the forecasted period. Newly launched drugs help in providing relief from bowel syndrome present especially in patients suffering from constipation. High research and development in the pharmaceutical industry will provide various growth opportunities at the end of the gastrointestinal drugs market forecasted period.


Restraints


Though there are various driving factors and growth opportunities available in the global gastrointestinal drugs market but some factors restraint its growth. The high cost of raw material used in manufacturer gastrointestinal drugs is the major factor that hampers its growth. Also, the increasing presence of the counterfeit drug is another factor that restricts its growth. The high amount of expenditure on research and development also restrain the gastrointestinal drugs market growth.


Value Chain Analysis


The gastrointestinal drugs market is growing rapidly in the global market owing to various benefits provided by it. It helps in providing relief during the pain caused by gastric diseases. There are various types of gastric drugs namely antidiarrheal drugs, antinauseants and laxatives, anti-inflammatory drugs, biologics, acid neutralizers, biologics, and many others available in the gastrointestinal drugs market. This drug also helps in treating various other stomach-related issues. This drug does not have worse side effects and can be consumed by teenagers as well.


Market Segmentation


The gastrointestinal drugs market has been divided all across the globe based on the drug class, application, route of administration, and distribution channel.


Based on the Drug Class


The market for gastrointestinal drugs has been divided all across the globe based on the drug class into antiemetic and antinauseants, antidiarrheal and laxatives, anti-inflammatory drugs, biologics, acid neutralizers, and many others. The acid neutralizer is further sub-divided into proton pump inhibitors, H2 antagonists, and antacids.


Based on the Application


The market for gastrointestinal drugs has been divided all across the globe based on the application into gastroenteritis, celiac disease, Crohn’s disease, irritable bowel syndrome, inflammatory ulcerative Colitis, and many others.


Based on the Route of Administration


The market for gastrointestinal drugs has been divided all across the globe based on the route of administration into rectal, parenteral, and oral.


Based on the Distribution Channel


The market for gastrointestinal drugs has been divided all across the globe based on the distribution channel into hospital pharmacies, online pharmacies, and retail pharmacies.


Regional Analysis


The market has been divided all across the globe based on the region into the American region, European region, Asia-Pacific region, and the Middle East and African region. The largest market in the global market is held by the American region owing to increasing healthcare expenditure coupled with increasing digestive disorders. The presence of a well-established healthcare sector is another driving factor in this region.


The second-largest market share in the global gastrointestinal drugs market is held by the European region owing to increasing investment in the healthcare industry coupled with increasing awareness regarding digestive diseases and treatment. Increasing demand for the most efficient and effective treatment is another driving factor in this region.


The third-largest market share in the global gastrointestinal drugs market is held by the Asia-Pacific region owing to the presence of highly populated countries like China and India. An increasing number of patients, a rising geriatric population, and rising investments initiatives taken by the government for healthcare facilities drive the growth in the Asia-Pacific region.


The least growth was observed in the Middle East and African region owing to low healthcare infrastructure, and low economic development in this region. Poor health facilities also restrict growth, especially in the African region.


Competitive Landscape


The most prominent major key players in the gastrointestinal drugs global market all across the globe are mentioned below:



  • Takeda Pharmaceuticals

  • Allergan Plc

  • Novo Nordisk A/S

  • AstraZeneca Plc

  • AbbVie Inc.

  • Valeant Pharmaceuticals Inc.

  • Johnson and Johnson

  • Bayer AG

  • Boehringer Ingelheim GmbH

  • GlaxoSmithKline Plc.

  • Jansssen Biotech Inc.

  • Sanofi


These major key players use various strategies to sustain gastrointestinal drugs market position in the gastrointestinal drugs market in the global market by going for mergers, and acquisitions, by collaborating, setting up a new joint venture, establishing a partnership, developing a new production process, developing a new product line, innovation in the existing product, and many others to expand their customer base in the untapped market of the gastrointestinal drug all across the globe.


Recent Developments



  • In November 2018, Tenapanor drug has received acceptance from New Drug Application (NDA), and FDA by Ardelyx. This drug is a sodium transporter NHE3 that helps in treating constipation.

  • In June 2019, an oral sodium transporter NHE3 inhibitor has been filed with NDS by Knight Therapeutics Inc. It helps in treating irritable bowel syndrome for Canadian patients.

  • In March 2020, approval was granted for Pizensy (lactitol) from the United States Food and Drug Administration (FDA) by Sebela Pharmaceuticals. This drug will help in treating (CIC) chronic idiopathic constipation prevailing commonly in adults.

  • In March 2021, a phase III clinical trial was initiated by Janssen Research and Development, LLC to evaluate the safety of ustekinumab. This trial will help in treating Crohn’s disease in pediatric patients ranging from moderate level to severe levels.

  • Johnson and Johnson are spending a huge amount of money on research and development which will help the company to sustain its global gastrointestinal drugs market position. This will also help in getting an upper edge over its competitors.


Report Overview


This global gastrointestinal drugs market research report consists of the following elements mentioned below:



  • Market Overview

  • COVID 19 Analysis

  • Market Dynamics

  • Value Chain Analysis

  • Market Segmentation

  • Regional Analysis

  • Competitive Landscape

  • Recent Developments


This market research report contains factors that drive the growth of the gastrointestinal drugs market in the global market along with the factors that restrict its growth in the global market. The opportunities available for growth during the forecasted period are mentioned. The impact of COVID 19 on the sales revenue of the gastrointestinal drugs market all across the globe is mentioned. The future growth rate during the forecasted period is estimated and mentioned.


Intended Audience


Biotechnology companies, government organizations, healthcare organizations, healthcare providers, research and development (R & D) companies, gastrointestinal drugs manufacturing companies, and many others.



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 75.56 billion
  CAGR   5.03% (2020-2030)
  Base Year   2019
  Forecast Period   2022-2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Class, Route of Administration, Application and Distribution Channel
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, AstraZeneca Plc, AbbVie Inc., Valeant Pharmaceuticals Inc., Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., and Sanofi
  Key Market Opportunities   high raw material costs and growing presence of counterfeit drugs
  Key Market Drivers

  • increasing prevalence of gastrointestinal diseases
  • rising investments and funding in the field of life science research


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Gastrointestinal drugs market valuation can touch 75.56 billion by 2030.

    Gastrointestinal drugs market is expected to exhibit a CAGR of 5.03% from 2020-2030.

    Gastrointestinal drugs market is driven by the alarming cases of GI among the masses.

    Presence of counterfeit drugs and high raw material costs can restrain the global gastrointestinal drugs market growth.

    GlaxoSmithKline Plc., Janssen Biotech Inc., Johnson & Johnson, Valeant Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Takeda Pharmaceuticals, Allergan Plc, Bayer AG, Sanofi, AstraZeneca Plc, Novo Nordisk A/S, and AbbVie Inc. are major players of the global gastrointestinal drugs market.